Latest Biotech News

A pivotal Phase 3 trial reported encouraging results for lucerastat, an oral therapy for Fabry disease, showing meaningful clinical signals versus placebo in key endpoints. Trial investigators and...

Researchers described new imidazotetrazine derivatives that restore sensitivity in glioblastoma models resistant to temozolomide, the longstanding backbone chemotherapy for GBM. Preclinical data...

Two diagnostics-led companies reported preliminary Q4 gains driven by testing volume. Tempus said preliminary Q4 revenue was about $367 million—an 83% year‑over‑year increase—attributing growth...

Two public life‑science tool and diagnostics firms posted preliminary quarterlies with testing and consumables at the center. 10x Genomics reported expected Q4 revenue of $166 million—above...

Eikon Therapeutics filed to go public after raising more than $1 billion in private capital since 2019. The company, led by former Merck executives including Roger Perlmutter and Roy Baynes, said...

Mirador Therapeutics closed a $250 million Series B to advance a precision-immunology portfolio and signaled plans to consider an IPO later in the year. The financing will fund continued clinical...

Tempus reported preliminary fourth-quarter revenue of about $367 million, up roughly 83% year over year, and beat Street estimates. The Chicago-based company attributed the gain primarily to...

Guardant Health said preliminary fourth-quarter revenue rose about 39% to roughly $280 million, topping consensus, as oncology test volumes and its Shield screening product expanded. The company...

10x Genomics reported preliminary fourth-quarter revenue of $166 million, beating estimates as consumables revenue rose about 6% year over year despite a decline in instrument sales. The company...

Veracyte reported preliminary Q4 revenue of $138–$140 million, topping consensus, and raised guidance for 2026 with expected double-digit revenue growth. The South San Francisco diagnostics firm...

Castle Biosciences expects preliminary full-year 2025 revenue of $340 million, above prior guidance, driven by a 37% year-over-year increase in test reports. The Friendswood, Texas firm delivered...

A pivotal Phase 3 trial of lucerastat, an oral therapy for Fabry disease, produced promising results pointing to clinical benefit in the rare lysosomal storage disorder, according to a new trial...

Stoke Therapeutics and the FDA did not agree on an accelerated submission for zorevunersen, Stoke’s candidate for Dravet syndrome, after a December meeting. Regulators asked Stoke to provide...

Researchers in China introduced DrugCLIP, an AI framework that screens millions of small molecules against thousands of protein targets in hours — a reported acceleration up to ten million times...

10x Genomics said preliminary Q4 revenue of $166 million, modestly above Street expectations, driven largely by a roughly 6% year-over-year rise in consumables sales. The company flagged a steep...

Stoke Therapeutics and the FDA failed to reach agreement on an accelerated filing pathway for zorevunersen, the company’s treatment for Dravet syndrome, after a December meeting. Regulators did...

Mirador Therapeutics closed a $250 million Series B to advance precision medicines for immune diseases and signaled potential plans for an IPO later in the year, the company told Endpoints News....

Eikon Therapeutics filed for a U.S. IPO, a test of whether recent market optimism can sustain new biotech listings, BioCentury reported. Separately, Aktis received a warm reception in public...

Veradermics, a Connecticut biotech developing an oral formulation of the hair‑growth drug Rogaine, filed for an initial public offering to raise capital for clinical development, the company...

Phanes Therapeutics presented positive Phase 2 data at ASCO GI showing spevatamig (PT886), a bispecific targeting CLDN18.2 and CD47, produced encouraging results in combination with chemotherapy...